Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Menopause. 2009;16(3):529–533. doi: 10.1097/gme.0b013e31818fb0c2

Figure 1.

Figure 1

Immunostaining of HOXA13 in vaginal specimens obtained from a patient with normal pelvic support with inlay of immunostaining with rabbit IgG as the negative control (1A.), a patient with normal pelvic support treated with leuprolide acetate (1B.), a premenopausal patient with POP (1C.) and a postmenopausal patient with POP (1D.) (magnification 60x)